We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, and others. Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, and others.
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing, with top-line results anticipated in 2H’25 Building a neuromuscular franchise with DNTH103; Phase 2 trial in Multifocal Motor...
NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
NEW YORK and WALTHAM, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of...
NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) initiated in Q1’24 with top-line results anticipated in 2H’25 $389 million of pro forma cash, including $216 million of net proceeds...
NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the...
Top-line results from gMG MaGic trial anticipated in 2H 2025 Building a neuromuscular franchise with DNTH103 through additional planned Phase 2 trials in Multifocal Motor Neuropathy (MMN) and...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.03 | -3.88825972065 | 26.49 | 29.66 | 25 | 87780 | 26.78635089 | CS |
| 4 | 2.22 | 9.55249569707 | 23.24 | 29.66 | 19.73 | 118088 | 23.92098069 | CS |
| 12 | -0.67 | -2.5641025641 | 26.13 | 33.77 | 19.73 | 156704 | 25.87305368 | CS |
| 26 | 13.96 | 121.391304348 | 11.5 | 33.77 | 6.58 | 115582 | 23.50667022 | CS |
| 52 | 15.06 | 144.807692308 | 10.4 | 33.77 | 6.58 | 89386 | 22.64772065 | CS |
| 156 | 15.06 | 144.807692308 | 10.4 | 33.77 | 6.58 | 89386 | 22.64772065 | CS |
| 260 | 15.06 | 144.807692308 | 10.4 | 33.77 | 6.58 | 89386 | 22.64772065 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
